Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-myeloablative HCT for Sickle Cell Anemia
NCT00029393Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Aug 2001
- Primary completion
- Jul 2007
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab and sirolimus in sickle cell anemia (SCA), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Stable donor cell engraftment. Started Aug 2001; status: completed.
02
Drugs
alemtuzumabsirolimus
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT00029393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00029393.